Stockreport

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical com [Read more]